This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
CLK2 · Western blot design guide
CLK2 Western Blot Planning Guide
Plan a CLK2 Western blot around the catalog-observed 60.1 kDa band, image-backed A05206-2 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
CLK2 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 60.1 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Lung | |
| Negative control | Skeletal muscle |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 60.1 kDa |
| ⓘ | Localization | Nucleus / Nucleus |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Sample controls for CLK2 Western blot
🧪Use Lung as the first positive-control candidate and Skeletal muscle as the HPA Not detected negative candidate.
Positive control: Lung (High)
Negative control: Skeletal muscle (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for CLK2
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart on each tissue page — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Lung | Reported tissue cells | High | Protein (HPA) | HPA → |
| Breast | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Appendix | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Bone marrow | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 1
What Is the Expected CLK2 Western Blot Band Size?
Use the product-observed 60.1 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 60.1 kDa | Matches the authoritative product WB observation. |
| 60.1 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected CLK2 appearancePlan around 60.1 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 60.1 kDa; use this as the primary experimental expectation. |
| Calculated mass | 60.1 kDa from UniProt P49760; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A05206-2. |
| Situation | Likely cause | Next action |
|---|---|---|
| 60.1 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing CLK2 band
A05206-2 · CLK2Observed 60.1 kDa · product-specific WB image
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Section 2
Real Curated CLK2 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Lung |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A05206-2 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 4
Advanced CLK2 Western Blot Tips
Deeper troubleshooting and optimisation questions for CLK2, answered from its protein features.
Which band should guide the blot?
Use 60.1 kDa, the observation attached to the authoritative A05206-2 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 60.1 kDa expectation.
Which positive control should I start with?
Start with Lung, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Skeletal muscle as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for CLK2 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A05206-2 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
Compare only the supplied target-verified records: PMC5042015, PMC11082251, PMC10671053.
Boster reagents
CLK2 Western Blot Reagents
Human/Mouse/Rat-reactive CLK2 Western blot reagents with authoritative product imagery.
Real WB data
Anti-CLK2 Antibody Picoband®
Cat # A05206-2
Reactivity: Human, Mouse, Rat
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P49760
- Human Protein Atlas — CLK2
- A05206-2 product record
- PMC5042015 — Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a/p27 in glioblastoma.
- PMC11082251 — CLK2 mediates IκBα-independent early termination of NF-κB activation by inducing cytoplasmic redistribution and degradation.
- PMC10671053 — Genetic Heterogeneity Underlying Phenotypes with Early-Onset Cerebellar Atrophy.